amphotericin-b and Dermatitis

Halcinonide-neomycin-amphotericin (HNA) cream was evaluated in the treatment of cutaneous candidiasis and inflammatory dermatoses. The anti-candidal properties of HNA were assessed in a parallel comparison with iodochlorhydroxyquin-hydrocortisone (I-HC) as the control drug. The overall therapeutic response with HNA was excellent in 38 (95%) of 40 patients as compared to 17 (43%) of 40 treated with I-HC. In 50 patients treated for psoriasis, eczematous dermatitis, or neurodermatitis, HNA was evaluated in a paired comparison with hydrocortisone (HC). The overall therapeutic response with HNA was excellent in 36 (72%) patients as compared to 18 (36%) with HC. There were no adverse reactions with HNA or the control drugs.

Topics: Administration, Topical; Adolescent; Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Candidiasis, Cutaneous; Child; Clinical Trials as Topic; Clioquinol; Dermatitis; Drug Combinations; Female; Halcinonide; Humans; Hydrocortisone; Male; Middle Aged; Neomycin; Pregnenediones; Time Factors

Fifty patients with a diagnosis of psoriasis, eczematous dermatitis, atopic dermatitis, or neurodermatitis and with bilateral symmetric lesions of equal severity participated in this study. A double-blind paired comparison technique was used in which halcinonide-neomycin-amphotericin ointment was applied to the lesions on one side of the body and hydrocortisone ointment to similar lesions on the other side according to a randomized schedule. The halcinonide-containing combination was statistically superior (p less than 0.05) to hydrocortisone ointment in the treatment of psoriasis patients. No statistically significant difference between the two drugs was obtained for the three other indications studied. No side effects with either ointment were observed. Halcinonide as formulated in this combination is an effective and safe corticosteroid.

Topics: Administration, Topical; Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Clinical Trials as Topic; Dermatitis; Dermatitis, Atopic; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydrocortisone; Infant; Male; Neomycin; Neurodermatitis; Ointments; Pregnenediones; Psoriasis

Topics: Administration, Topical; Adolescent; Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Candidiasis, Cutaneous; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis; Drug Combinations; Female; Glucocorticoids; Humans; Male; Middle Aged; Neomycin; Pregnenediones

One hundred patients participated in the studies of cutaneous candidiasis and steroid-responsive dermatoses. Seventy patients with the former diagnosis were treated with either halcinonide-neomycin-amphotericin or hydrocortisone-iodochlorhydroxyquin ointment combinations on a double-blind parallel comparison basis. Similar results were obtained after both therapies. Thirty patients with symmetrical bilateral lesions of steroid-responsive dermatoses were treated with halcinonide-neomycin-amphotericin cream on the lesions on one side of the body and hydrocortisone-iodochlorhydroxyquin cream on the opposite side. A double-blind design was used in directly comparing the response to each of the two drugs. Considering the results of all dermatoses together the test combination was statistically superior to the control cream (p less than 0-05). However, while numerical superiority of good responses to the halcinonide combination was recorded in psoriasis, no statistical significance could be derived due to the limited number of cases. No side-effects occurred with any drug combination use. In the opinion of the authors halcinonide-neomycin-amphotericin cream and ointment are safe and effective in the treatment of cutaneous candiasis and steroid-responsive dermatoses.

Topics: Administration, Topical; Adolescent; Adult; Amphotericin B; Anti-Inflammatory Agents; Candidiasis, Cutaneous; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis; Double-Blind Method; Drug Combinations; Female; Glucocorticoids; Humans; Infant; Infant, Newborn; Male; Middle Aged; Neomycin; Patient Dropouts; Pregnenediones; Psoriasis

This study evaluated the in vivo activity of liposomal amphotericin B (L-AMB) and deoxycholate amphotericin B (D-AMB) in a murine model of disseminated infection caused by Exophiala dermatitidis. Cyclophosphamide-treated neutropenic ddY mice were inoculated intravenously with conidial suspensions of E. dermatitidis IFM 4827 or IFM 53409. The maximum tolerated doses of L-AMB and D-AMB were set at 10 mg/kg and 1 mg/kg, respectively. Four hours after infection, a single dose of L-AMB (0.3 to 10 mg/kg) or D-AMB (0.1 to 1 mg/kg) was administered intravenously. The efficacy of the antifungal treatment was assessed by the survival time over two weeks and the tissue fungal burdens 4 days after infection. L-AMB at a dose of > or =1 mg/kg significantly prolonged the survival time of mice infected with either strain compared with that of the control group. Percent survivals in the 10 mg/kg L-AMB-treated group (100% and 75%) were higher than those in the 1 mg/kg D-AMB-treated group (20% and 37.5%) in the IFM 4827 and IFM 53409 models, respectively. In the IFM 4827 model, 10 mg/kg L-AMB exhibited greater efficacy than 1 mg/kg D-AMB in terms of reducing the tissue fungal burdens (blood, lung, liver, spleen, and kidneys). These findings suggest that L-AMB was effective in the treatment of experimental disseminated E. dermatitidis infection, and the efficacy of L-AMB was superior to that of D-AMB.

Topics: Amphotericin B; Animals; Antifungal Agents; Deoxycholic Acid; Dermatitis; Dermatomycoses; Exophiala; Male; Mice

We report two cases of post-kala-azar dermal leishmaniasis (PKDL), which had subsequently developed after successful treatment of visceral leishmaniasis with miltefosine. Both patients had maculo-nodular lesions all over the body, and they were diagnosed as PKDL by parasitologic examination for Leishmania donovani bodies in a skin snip of lesions. Patients were put on amphotericin B and responded very well for nodular lesions with one course of treatment. However, longer duration of the treatment is needed for total clearance of macular lesions from body surface in PKDL cases. This is the first case report of PKDL in India, which developed after successful treatment of visceral leishmaniasis with miltefosine.

Topics: Adult; Amphotericin B; Antiprotozoal Agents; Dermatitis; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Phosphorylcholine

We describe a case of sporotrichosis that disseminated to involve multiple nerves after initiation of immunosuppressive therapy and then precipitously worsened after withdrawal of therapy. This case illustrates that multiple mononeuropathies are not always caused by vasculitis, and a correct pathological diagnosis should be established before treatment. Based on clinical and pathological features, the mechanism of neuropathy may have been due to either direct nerve infection or a bystander effect of inflammatory/immune damage or, perhaps more likely, to both mechanisms.

Topics: Abscess; Amphotericin B; Anti-Bacterial Agents; Anti-Inflammatory Agents; Debridement; Dermatitis; Diagnostic Errors; Disease Progression; Forearm; Granulomatous Disease, Chronic; Humans; Immunosuppressive Agents; Inflammation; Male; Middle Aged; Muscle Weakness; Muscle, Skeletal; Pain; Peripheral Nerves; Peripheral Nervous System Diseases; Sporothrix; Sporotrichosis; Treatment Outcome; Wrist Joint

Topics: Adult; Amphotericin B; Candida; Candida albicans; Candidiasis; Dermatitis; Facial Dermatoses; Female; Fluocinolone Acetonide; Humans; Nystatin

Topics: Adrenal Cortex Hormones; Amphotericin B; Anti-Bacterial Agents; Dermatitis; Facial Dermatoses; Humans; Nasolabial Fold; Skin Diseases; Tetracycline